上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会 会议资料 二零二五年八月 上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会会议资料目录 一、会议议程 二、会议须知 三、股东会审议议案 1、审议《公司关于更换会计师事务所的议案》 上海康德莱企业发展集团股份有限公司 2025 年第一次临时股东会会议议程 会议时间：2025 年 9 月 11 日（周四）上午 10:00 会议程序： | 序号 | 会议议案 | | --- | --- | | 1 | 《公司关于更换会计师事务所的议案》 | | 三、通过会议计票人、监票人； | | 为维护投资者的合法权益，确保此次股东会议的议事效率，根据中国证券监 督管理委员会发布的《上市公司股东会规则》、《上市公司治理准则》和《公司章 程》等相关规定，特制定本会议须知。 四、现场会议投票表决、计票； 五、股东发言； 六、会议发言解答； 七、宣布现场会议表决结果； 八、由会议见证律师宣读法律意见书； 九、宣布会议结束。 会议地点：上海市嘉定区高潮路 658 号四楼会议室 参会人员：公司股东、董事、监事、高级管理人员等 见证律师：德恒上海律师事务所律师 ...

证券代码：603987 证券简称：康德莱 公告编号：2025-019 上海康德莱企业发展集团股份有限公司 第五届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海康德莱企业发展集团股份有限公司（以下简称"公司"）第五届监事会 第十四次会议（以下简称"会议"）于 2025 年 8 月 25 日在上海市嘉定区高潮路 658 号会议室以现场结合通讯表决方式召开，会议通知及相关文件已于 2025 年 8 月 15 日以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。会议 由监事会主席方剑宏先生主持，财务总监和董事会秘书列席会议。本次会议符合 《中华人民共和国公司法》《上海证券交易所股票上市规则》等有关法律、行政 法规、部门规章、规范性文件和《上海康德莱企业发展集团股份有限公司章程》 的规定。 二、监事会会议审议情况 （一）审议通过了《公司 2025 年半年度报告》； 监事会认为：公司 2025 年半年度报告的编制和审议程序符合法律、法规、 公司章程和公司内部控制制度 ...

证券代码：603987 证券简称：康德莱 公告编号：2025-017 上海康德莱企业发展集团股份有限公司 第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海康德莱企业发展集团股份有限公司（以下简称"公司"）第五届董事会 第十八次会议（以下简称"会议"）于 2025 年 8 月 25 日在上海市嘉定区高潮路 658 号会议室以现场结合通讯表决方式召开，会议通知及相关会议文件于 2025 年 8 月 15 日以电子邮件方式向全体董事、监事及高级管理人员发出。会议应出 席董事 9 名，实际出席董事 9 名。会议由董事长张宪淼先生主持，公司监事、财 务总监及董事会秘书列席会议。本次会议符合《中华人民共和国公司法》《上海 证券交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文件和《上 海康德莱企业发展集团股份有限公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《公司 2025 年半年度报告》； 公司第五届董事会审计委员会在本次董事会召开前已就本议案发表了事 ...

上海康德莱企业发展集团股份有限公司2025 年半年度报告 公司代码：603987 公司简称：康德莱 上海康德莱企业发展集团股份有限公司 2025 年半年度报告 1 / 208 上海康德莱企业发展集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张维鑫、主管会计工作负责人沈晓如及会计机构负责人（会计主管人员）沈晓 如声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2025年上半年公司不进行利润分配或公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投 资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公 ...

Core Insights - The company reported a revenue of 1.125 billion yuan for the first half of 2025, reflecting a year-on-year growth of 0.17% [1] - The net profit attributable to shareholders of the listed company reached 125 million yuan, showing an increase of 18.94% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 123 million yuan, with a year-on-year growth of 19.40% [1] - The basic earnings per share were 0.28 yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdelai, a company in the medical device industry, which is currently facing a decline in stock price and revenue [1][2] - As of August 14, Kangdelai's stock closed at 8.99 yuan, down 3.75%, with a rolling PE ratio of 18.22 times and a total market capitalization of 3.927 billion yuan [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Kangdelai at the 39th position within the industry [1][2] Group 2 - Kangdelai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices [1] - The company reported a revenue of 548 million yuan for Q1 2025, a year-on-year decrease of 3.82%, while net profit was 60.7042 million yuan, showing a slight increase of 0.28% [1] - The sales gross margin for the latest quarter was 32.02% [1]

Group 1 - The core viewpoint of the news is that Kangdelai (603987) has shown a slight increase in stock price and has reported its latest financial performance, indicating a mixed trend in revenue and profit [1] - As of August 13, 2025, Kangdelai's stock closed at 9.34 yuan, up 0.97%, with a turnover rate of 7.46% and a trading volume of 325,900 hands, amounting to a transaction value of 301 million yuan [1] - The net inflow of main funds today was 13.61 million yuan, accounting for 4.53% of the transaction value, with significant contributions from large orders [1] Group 2 - For the first quarter of 2025, Kangdelai reported total operating revenue of 548 million yuan, a year-on-year decrease of 3.82%, while the net profit attributable to shareholders was 60.70 million yuan, a year-on-year increase of 0.28% [1] - The company has a current ratio of 1.639, a quick ratio of 1.280, and a debt-to-asset ratio of 28.70% [1] - Kangdelai has made investments in 11 companies, participated in 236 bidding projects, and holds 52 trademark registrations and 382 patents, along with 319 administrative licenses [2]

Group 1 - The core viewpoint of the article highlights that Kangdelai's stock price closed at 9.25 yuan, with a PE ratio of 18.75, marking a new low in 387 days, and a total market capitalization of 4.04 billion yuan [1] - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, placing Kangdelai at the 39th position within the industry [1] - As of the first quarter of 2025, three institutions hold shares in Kangdelai, with a total of 163,900 shares valued at 0.01 million yuan [1] Group 2 - Kangdelai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices [1] - The company has established a Shanghai-level enterprise technology center for R&D, and its subsidiary in Zhejiang has set up a provincial research institute for puncture medical devices [1] - The latest financial results for the first quarter of 2025 show that Kangdelai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, with a gross profit margin of 32.02% [1]

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

通过天眼查大数据分析，上海康德莱企业发展集团股份有限公司共对外投资了11家企业，参与招投标项 目235次，知识产权方面有商标信息52条，专利信息382条，此外企业还拥有行政许可319个。 来源：金融界 康德莱最新一期业绩显示，截至2025一季报，公司营业总收入5.48亿元、同比减少3.82%，归属净利润 6070.42万元，同比增长0.28%，扣非净利润5997.00万元，同比增长1.73%，流动比率1.639、速动比率 1.280、资产负债率28.70%。 天眼查商业履历信息显示，上海康德莱企业发展集团股份有限公司，成立于1998年，位于上海市，是一 家以从事专用设备制造业为主的企业。企业注册资本43679.088万人民币，实缴资本15769万人民币。公 司法定代表人为张维鑫。 金融界消息 截至2025年8月11日收盘，康德莱（603987）报收于9.04元，下跌2.06%，换手率7.29%，成 交量31.82万手，成交金额2.89亿元。 资金流向方面，今日主力资金净流出2941.83万元，占比成交额10.17%。其中，超大单净流出2768.98万 元、占成交额9.58%，大单净流出172.86万元、占成交 ...